Skip to main content
Premium Trial:

Request an Annual Quote

Jack Crowley, Kavita Patel, Garry Nicholson

Personal Genome Diagnostics has appointed Jack Crowley as its chief financial officer. Crowley most recently served as CFO at Lantheus Medical Imaging, where he led a transition from a private equity-backed to a publicly-traded global life sciences company. Prior to serving as CFO, Crowley also served as Lantheus' chief accounting officer, VP of finance, and global corporate controller. He also served as director of finance and assistant corporate controller at Biogen and director of accounting at Thermo Fischer Scientific. A Certified Public Accountant, he holds an MBA from the University of Massachusetts and a BS in Business Administration from Westfield State University.

PGDx has also appointed Kavita Patel and Garry Nicholson to its board of directors. Patel has served in the Obama Administration as director of policy for the Office of Intergovernmental Affairs and Public Engagement in the White House. Prior to the White House, she served as deputy staff director on health on the late Senator Edward Kennedy's staff. She also serves on the board of directors at Dignity Health and SSM Health Care. 

Nicholson currently serves as director at Five Prime Therapeutics, G1 Therapeutics, Tmunity Therapetics Inc, and SQZ Biotechnology. He previously served as President and CEO of XTuit Pharmaceuticals, as well as a member of the firm's board of directors. Prior to that, he served as president of Pfizer Oncology. He has also served on the Pfizer Foundation's board of directors and was a member of the firm's Portfolio, Strategy, and Investment Committee. In addition, Nicholson previously held leadership positions in the oncology division of Eli Lily. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.